February 3, 2017 /

Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Mission DMD: FibroGen’s Anti-Fibrosis Program (February 2017)

On February 1, 2017, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is currently being conducted to investigate Pamrevlumab in Duchenne.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo